Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.45 |
| ▸ | CTSB | P07858 | 5/20 | 0.43 |
| ▸ | CTSL | P07711 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | AKR1B10 | O60218 | 5/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 5/20 | 0.38 |
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23931216 | 1.00 | APP (0.45) | APPCTSBCTSLTDP1PTPN1 | |
| SCHEMBL23931215 | 1.00 | APP (0.45) | APPCTSBCTSLTDP1PTPN1 | |
| SCHEMBL16612399 | 1.00 | APP (0.45) | APPCTSBCTSLTDP1PTPN1 | |
| SCHEMBL23931214 | 1.00 | APP (0.45) | APPCTSBCTSLTDP1PTPN1 | |
| SCHEMBL16612396 | 1.00 | APP (0.45) | APPCTSBCTSLTDP1PTPN1 | |
| SCHEMBL28809818 | 0.84 | ERN1 (0.32) | PTPN1MAPT | |
| SCHEMBL16612429 | 0.84 | ERN1 (0.32) | PTPN1MAPT | |
| SCHEMBL16612431 | 0.84 | ERN1 (0.32) | PTPN1MAPT | |
| SCHEMBL16612610 | 0.84 | CYP1A1 (0.47) | APPMAPTBACE1CYP1A1CYP1B1 | |
| SCHEMBL30284575 | 0.84 | CYP1A1 (0.47) | APPMAPTBACE1CYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240415787-A1 | COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2024-12-19 | — | — | US | claimed |
| EP-4397304-A1 | COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES | Shin Poong Pharmaceutical Co., Ltd. (KR) | 2024-07-10 | — | — | EP | claimed |
| CN-117897145-A | Composition for treating or preventing obesity or obesity-related liver diseases comprising verbenone derivatives | 韩国新丰制药株式会社 | 2024-04-16 | — | — | CN | claimed |
| US-10710951-B2 | Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2020-07-14 | — | — | US | claimed |
| EP-2857007-B1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | UNIV KOREA RES & BUS FOUND (KR) | 2018-03-28 | — | — | EP | claimed |
| US-20170166505-A1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2017-06-15 | — | — | US | claimed |
| US-9603842-B2 | Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2017-03-28 | — | — | US | claimed |
| US-20150148362-A1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2015-05-28 | — | — | US | claimed |
| EP-2857007-A1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | Korea University Research and Business Foundation (KR) | 2015-04-08 | — | — | EP | claimed |
| US-20240415787-A1 | COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2024-12-19 | — | — | US | disclosed |
| EP-4397304-A1 | COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES | Shin Poong Pharmaceutical Co., Ltd. (KR) | 2024-07-10 | — | — | EP | disclosed |
| CN-117897145-A | Composition for treating or preventing obesity or obesity-related liver diseases comprising verbenone derivatives | 韩国新丰制药株式会社 | 2024-04-16 | — | — | CN | disclosed |
| US-10710951-B2 | Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2020-07-14 | — | — | US | disclosed |
| EP-2857007-B1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | UNIV KOREA RES & BUS FOUND (KR) | 2018-03-28 | — | — | EP | disclosed |
| US-20170166505-A1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2017-06-15 | — | — | US | disclosed |
| US-9603842-B2 | Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2017-03-28 | — | — | US | disclosed |
| US-20150148362-A1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2015-05-28 | — | — | US | disclosed |
| EP-2857007-A1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | Korea University Research and Business Foundation (KR) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166505-A1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | CASP3, DCX, BAX | APP 96/4885CTSB 1690/4885CTSL 3242/4885 |
| US-10710951-B2 | Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease | CASP3, DCX, BAX | APP 96/4885CTSB 1690/4885CTSL 3242/4885 |
| US-20240415787-A1 | COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES | SMAD3, TGFB1, TGFB2 | APP 1814/4885CTSB 4083/4885CTSL 4642/4885 |
| US-20150148362-A1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | CASP3, DCX, BAX | APP 96/4885CTSB 1690/4885CTSL 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.